Profund Advisors’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-2,268
| Closed | -$391K | – | 1031 |
|
|
2022
Q1 | $391K | Buy |
2,268
+400
| +21% | +$59.8K | 0.02% | 732 |
|
|
2021
Q4 | $302K | Sell |
1,868
-129
| -6% | -$20.7K | 0.01% | 982 |
|
|
2021
Q3 | $298K | Sell |
1,997
-140
| -7% | -$29.1K | 0.01% | 960 |
|
|
2021
Q2 | $524K | Sell |
2,137
-59
| -3% | -$15.5K | 0.02% | 635 |
|
|
2021
Q1 | $581K | Sell |
2,196
-728
| -25% | -$205K | 0.02% | 508 |
|
|
2020
Q4 | $858K | Buy |
2,924
+112
| +4% | +$28.7K | 0.04% | 352 |
|
|
2020
Q3 | $665K | Buy |
2,812
+859
| +44% | +$195K | 0.03% | 372 |
|
|
2020
Q2 | $388K | Sell |
1,953
-158
| -7% | -$29.5K | 0.02% | 469 |
|
|
2020
Q1 | $387K | Sell |
2,111
-1,696
| -45% | -$302K | 0.03% | 422 |
|
|
2019
Q4 | $635K | Buy |
3,807
+327
| +9% | +$48.6K | 0.03% | 508 |
|
|
2019
Q3 | $456K | Buy |
3,480
+92
| +3% | +$12K | 0.02% | 633 |
|
|
2019
Q2 | $411K | Buy |
3,388
+207
| +7% | +$24.6K | 0.02% | 747 |
|
|
2019
Q1 | $392K | Sell |
3,181
-748
| -19% | -$93.9K | 0.02% | 758 |
|
|
2018
Q4 | $460K | Sell |
3,929
-1,620
| -29% | -$191K | 0.03% | 510 |
|
|
2018
Q3 | $693K | Sell |
5,549
-808
| -13% | -$89.2K | 0.03% | 572 |
|
|
2018
Q2 | $543K | Buy |
6,357
+409
| +7% | +$30K | 0.02% | 724 |
|
|
2018
Q1 | $359K | Buy |
5,948
+1,747
| +42% | +$99.5K | 0.01% | 1017 |
|
|
2017
Q4 | $221K | Sell |
4,201
-839
| -17% | -$44.2K | 0.01% | 1317 |
|
|
2017
Q3 | $282K | Buy |
5,040
+724
| +17% | +$38.3K | 0.01% | 1125 |
|
|
2017
Q2 | $271K | Sell |
4,316
-1,870
| -30% | -$109K | 0.01% | 1153 |
|
|
2017
Q1 | $316K | Sell |
6,186
-2,538
| -29% | -$121K | 0.01% | 1121 |
|
|
2016
Q4 | $372K | Buy |
8,724
+3,786
| +77% | +$161K | 0.02% | 1097 |
|
|
2016
Q3 | $234K | Sell |
4,938
-972
| -16% | -$48.5K | 0.01% | 1235 |
|
|
2016
Q2 | $298K | Buy |
5,910
+66
| +1% | +$3.33K | 0.01% | 1130 |
|
|
2016
Q1 | $282K | Buy |
+5,844
| New | +$225K | 0.01% | 1138 |
|
|
2015
Q3 | – | Sell |
-6,589
| Closed | -$262K | – | 1214 |
|
|
2015
Q2 | $262K | Sell |
6,589
-1,481
| -18% | -$46.1K | 0.01% | 1209 |
|
|
2015
Q1 | $216K | Buy |
+8,070
| New | +$228K | 0.01% | 1392 |
|
|
2014
Q1 | – | Sell |
-19,032
| Closed | -$278K | – | 1618 |
|
|
2013
Q4 | $278K | Sell |
19,032
-1,773
| -9% | -$28.5K | 0.01% | 1432 |
|
|
2013
Q3 | $358K | Buy |
+20,805
| New | +$309K | 0.02% | 1179 |
|
Other funds holding AMED
RP
BG
Profund Advisors's AMED Position: Q2 2022 in Review
Profund Advisors sold out of Amedisys (AMED) in Q2 2022, closing a stake of 2,268 shares — an estimated $391K sold.
Profund Advisors first reported a position in AMED in Q3 2013 and held it in 29 quarters. The position peaked at $858K in Q4 2020. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.
- Profund Advisors reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
- Profund Advisors sold 2,268 Amedisys shares in Q2 2022, an estimated $391K.
- Profund Advisors first reported a position in Amedisys in Q3 2013 and held it in 29 quarters.
- Profund Advisors's Amedisys position peaked at $858K in Q4 2020.
- 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.
Based on Profund Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.